专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060276521A1 Thiazole derivatives 失效
公开(公告)号：US20060276521A1
公开(公告)日：2006-12-07
申请号：US11505321
申请日：2006-08-17
申请人： Takayuki Inoue , Takashi Tojo , Masataka Morita , Mitsuru Ohkubo , Kousei Yoshihara , Akira Nagashima
发明人： Takayuki Inoue , Takashi Tojo , Masataka Morita , Mitsuru Ohkubo , Kousei Yoshihara , Akira Nagashima
IPC分类号： A61K31/427 , A61K31/426 , C07D417/02
CPC分类号： C07D417/06 , C07D277/46 , C07D277/48 , C07D277/56 , C07D417/12
摘要： A compound of the formula (I): R1—NH—X—Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.

2. 发明申请

US20060128770A1 Thiazole derivatives 审中-公开
标题翻译：噻唑衍生物
公开(公告)号：US20060128770A1
公开(公告)日：2006-06-15
申请号：US11345492
申请日：2006-02-02
申请人： Takayuki Inoue , Takashi Tojo , Masataka Morita , Mitsuru Ohkubo , Kousei Yoshihara , Akira Nagashima
发明人： Takayuki Inoue , Takashi Tojo , Masataka Morita , Mitsuru Ohkubo , Kousei Yoshihara , Akira Nagashima
IPC分类号： A61K31/427 , A61K31/426 , C07D417/02
CPC分类号： C07D417/06 , C07D277/46 , C07D277/48 , C07D277/56 , C07D417/12
摘要： A compound of the formula (I): R1—NH—X—Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.
摘要翻译：式（I）化合物：其中各符号如说明书中所定义，或其药学上可接受的盐可用作血管粘附蛋白-1（1R） VAP-1）抑制剂，药物组合物，预防或治疗VAP-1相关疾病，尤其是黄斑水肿的方法，该方法包括将有效量的化合物或其药学上可接受的盐给予哺乳动物等。

3. 发明授权

US07442715B2 Thiazole derivatives 失效
标题翻译：噻唑衍生物
公开(公告)号：US07442715B2
公开(公告)日：2008-10-28
申请号：US11505321
申请日：2006-08-17
申请人： Akira Nagashima , Takayuki Inoue , Mitsuru Ohkubo , Kousei Yoshihara , Takashi Tojo , Masataka Morita
发明人： Akira Nagashima , Takayuki Inoue , Mitsuru Ohkubo , Kousei Yoshihara , Takashi Tojo , Masataka Morita
IPC分类号： A61K31/427
CPC分类号： C07D417/06 , C07D277/46 , C07D277/48 , C07D277/56 , C07D417/12
摘要： A compound of the formula (I): R1—NH—X—Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.
摘要翻译：式（I）化合物：其中各符号如说明书中所定义，或其药学上可接受的盐可用作血管粘附蛋白-1（1R） VAP-1）抑制剂，药物组合物，预防或治疗VAP-1相关疾病，尤其是黄斑水肿的方法，该方法包括将有效量的化合物或其药学上可接受的盐给予哺乳动物等。

4. 发明授权

US07125901B2 Thiazole derivatives 有权
公开(公告)号：US07125901B2
公开(公告)日：2006-10-24
申请号：US10764529
申请日：2004-01-27
申请人： Takayuki Inoue , Takashi Tojo , Masataka Morita , Mitsuru Ohkubo , Kousei Yoshihara , Akira Nagashima
发明人： Takayuki Inoue , Takashi Tojo , Masataka Morita , Mitsuru Ohkubo , Kousei Yoshihara , Akira Nagashima
IPC分类号： A61K31/427 , C07D277/44
CPC分类号： C07D417/06 , C07D277/46 , C07D277/48 , C07D277/56 , C07D417/12
摘要： A compound of the formula (I): R1—NH—X—Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.

5. 发明申请

US20080015202A1 Thiazole Derivatives Having Vap-1 Inhibitory Activity 审中-公开
标题翻译：具有Vap-1抑制活性的噻唑衍生物
公开(公告)号：US20080015202A1
公开(公告)日：2008-01-17
申请号：US11574946
申请日：2005-09-08
申请人： Takayuki Inoue , Takashi Tojo , Masataka Morita
发明人： Takayuki Inoue , Takashi Tojo , Masataka Morita
IPC分类号： A61K31/426 , A61K31/445 , A61K31/497 , A61P27/02 , C07D411/00
CPC分类号： C07D417/10 , C07D277/46 , C07D417/06 , C07D417/12
摘要： A compound of the formula (I): U-V-W-X-Y-Z (I) wherein U is lower alkyl; V is —CONH— or —NR1CO— wherein R1 is a hydrogen or lower alkyl; W is a bond or lower alkylene; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond or lower alkylene; and Z is a group of the formula: wherein R2 is a group of the formula: -A-B-D-E-F-G wherein A is a bond or lower alkylene; B is a bond, —NH— or D is a bond, —CS— or —CO—; E is a bond or —NH—; F is a bond, —CO—, —O— or —SO2—; and G is lower alkyl, optionally protected amino, —OH, phenyl, R3 is lower alkyl, provided that when Z is a group of the formula: then G should not be amino, when Z is a group of the formula: then G should not be when Z is a group of the formula: and G is optionally protected amino, then D should be —CS—, or then A should be lower alkylene, B or E should be —NH— and F should be —CO—; or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor as well as a pharmaceutical composition and a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.
摘要翻译：式（I）的化合物：<？in-line-formula description =“In-line Formulas”end =“lead”？> UVWXYZ（I）<？in-line-formula description =“In-line Formulas” end =“tail”？>其中U是低级烷基; V是-CONH-或-NR 1 CO-，其中R 1是氢或低级烷基; W是键或低级亚烷基; X是衍生自任选取代的噻唑的二价残基; Y是键或低级亚烷基; 并且Z是下式的基团：其中R 2是下列基团：-A-B-D-E-F-G其中A是键或低级亚烷基; B是键，-NH-或D是键，-CS-或-CO-; E是键或-NH-; F是键，-CO - ， - O-或-SO 2 - 。并且G为低级烷基，任意保护的氨基，-OH，苯基，R 3为低级烷基，条件是当Z为下式基团时，则G不应为氨基，当Z为组式为：那么G不应该是当Z是下式的基团时：G是任意保护的氨基，那么D应该是-CS-，或者A应该是低级亚烷基，B或E应该是-NH- 而F应为-CO-; 或其药学上可接受的盐可用作血管粘附蛋白-1（VAP-1）抑制剂，以及用于预防或治疗VAP-1相关疾病，特别是黄斑水肿的药物组合物和方法，该方法包括施用有效的化合物或其药学上可接受的盐对受试者的量等。

6. 发明申请

US20090264399A1 HETEROCYCLIC JANUS KINASE 3 INHIBITORS 失效
标题翻译：杂交种JANUS KINASE 3抑制剂
公开(公告)号：US20090264399A1
公开(公告)日：2009-10-22
申请号：US11995445
申请日：2006-07-13
申请人： Takayuki Inoue , Takashi Tojo , Masataka Morita , Yutaka Nakajima , Keiko Hatanaka , Shohei Shirakami , Hiroshi Sasaki , Akira Tanaka , Fumie Takahashi , Koichiro Mukoyoshi , Yasuyuki Higashi , Akira Okimoto , Takeshi Hondo , Hitoshi Sawada
发明人： Takayuki Inoue , Takashi Tojo , Masataka Morita , Yutaka Nakajima , Keiko Hatanaka , Shohei Shirakami , Hiroshi Sasaki , Akira Tanaka , Fumie Takahashi , Koichiro Mukoyoshi , Yasuyuki Higashi , Akira Okimoto , Takeshi Hondo , Hitoshi Sawada
IPC分类号： A61K31/437 , C07D471/04 , C07D413/14 , C07D471/14 , A61K31/5377 , A61K31/397 , A61P25/00 , A61P37/06 , A61P35/00 , A61P35/02 , A61P11/06
CPC分类号： C07D471/14 , C07D519/00
摘要： The invention relates to compound of the formula (I) or its salt, wherein —R1, —R2, —R3, —R4, —R5, -M-, —X— and —Y═ are as defined in the description, their use of as, medicament, the process for their preparation and use for the treatment of JAK3 mediated diseases.
摘要翻译：本发明涉及式（I）或其盐的化合物，其中-R1，-R2，-R3，-R4，-R5，-M-，-X-和-Y-如说明书中所定义，它们使用as，药物，其制备方法和用于治疗JAK3介导的疾病。

7. 发明授权

US08163767B2 Heterocyclic Janus Kinase 3 inhibitors 失效
标题翻译：杂环Janus激酶3抑制剂
公开(公告)号：US08163767B2
公开(公告)日：2012-04-24
申请号：US11995445
申请日：2006-07-13
申请人： Takayuki Inoue , Takashi Tojo , Masataka Morita , Yutaka Nakajima , Keiko Hatanaka , Shohei Shirakami , Hiroshi Sasaki , Akira Tanaka , Fumie Takahashi , Koichiro Mukoyoshi , Yasuyuki Higashi , Akira Okimoto , Takeshi Hondo , Hitoshi Sawada
发明人： Takayuki Inoue , Takashi Tojo , Masataka Morita , Yutaka Nakajima , Keiko Hatanaka , Shohei Shirakami , Hiroshi Sasaki , Akira Tanaka , Fumie Takahashi , Koichiro Mukoyoshi , Yasuyuki Higashi , Akira Okimoto , Takeshi Hondo , Hitoshi Sawada
IPC分类号： A61K31/44 , C07D471/14
CPC分类号： C07D471/14 , C07D519/00
摘要： The invention relates to compound of the formula (I) or its salt, wherein —R1, —R2, —R3, —R4, —R5, -M-, —X— and —Y═ are as defined in the description, their use of as, medicament, the process for their preparation and use for the treatment of JAK3 mediated diseases.
摘要翻译：本发明涉及式（I）化合物或其盐，其中-R1，-R2，-R3，-R4，-R5，-M-，-X-和-Y =如说明书中所定义，它们使用as，药物，其制备方法和用于治疗JAK3介导的疾病。

8. 发明申请

US20070254931A1 Thiazole Derivatives Having Vap-1 Inhibitory Activity 审中-公开
标题翻译：具有Vap-1抑制活性的噻唑衍生物
公开(公告)号：US20070254931A1
公开(公告)日：2007-11-01
申请号：US11572772
申请日：2005-07-27
申请人： Takayuki Inoue , Takashi Tojo , Masataka Morita
发明人： Takayuki Inoue , Takashi Tojo , Masataka Morita
IPC分类号： A61K31/426 , A61P19/02 , A61P19/08 , A61P3/10 , A61P9/10 , C07D277/46
CPC分类号： C07D277/46
摘要： A compound of the formula (I), (II), (III) or (IV): wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.
摘要翻译：式（I），（II），（III）或（IV）的化合物：其中每个符号如说明书中所定义，或其药学上可接受的盐可用作血管粘附蛋白-1（VAP-1）抑制剂，药物组合物，预防或治疗VAP-1相关疾病，特别是黄斑水肿的方法，该方法包括向受试者施用有效量的化合物或其药学上可接受的盐等。

9. 发明授权

US06331521B1 Echinocandine derivatives with antimicrobial activity 失效
标题翻译：棘皮类衍生物具有抗菌活性
公开(公告)号：US06331521B1
公开(公告)日：2001-12-18
申请号：US09423654
申请日：1999-12-01
申请人： Yasuhiro Hori , Yasuhisa Tsurumi , Shigehiro Takase , Hiroshi Hatanaka , Kazutoshi Sakamoto , Seiji Hashimoto , Hidenori Ohki , Takashi Tojo , Keiji Matsuda , Kohji Kawabata
发明人： Yasuhiro Hori , Yasuhisa Tsurumi , Shigehiro Takase , Hiroshi Hatanaka , Kazutoshi Sakamoto , Seiji Hashimoto , Hidenori Ohki , Takashi Tojo , Keiji Matsuda , Kohji Kawabata
IPC分类号： A61K3800
CPC分类号： C07K7/56 , A61K38/00
摘要： The invention relates to new polypeptide compounds represented by the following formula [I]: wherein R1 is hydrogen, etc, R2 is hydrogen, etc, R3 is hydrogen, etc, and R4 is hydrogen, etc, or a salt thereof which have antimicrobial activities (especially, antifungal activities), inhibitory activity on &bgr;-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.
摘要翻译：本发明涉及由下式[I]表示的新的多肽化合物：其中R 1为氢等，R 2为氢等，R 3为氢等，R 4为氢等，或其具有抗微生物活性的盐，抗真菌活性），对β-1,3-葡聚糖合酶的抑制活性，其制备方法，包含其的药物组合物，以及用于预防和/或治疗感染性疾病包括卡氏肺囊虫感染的方法（例如卡氏肺囊虫肺炎）在人或动物中。

10. 发明授权

US5470827A Method of producing iturin A and antifungal agent for profound mycosis 失效
标题翻译：产生神经蛋白A的方法和深层真菌病的抗真菌剂
公开(公告)号：US5470827A
公开(公告)日：1995-11-28
申请号：US312911
申请日：1994-09-29
申请人： Yasushi Tanaka , Takashi Tojo , Kazuhiko Uchida , Jun Uno , Yasushi Uchida , Osamu Shida
发明人： Yasushi Tanaka , Takashi Tojo , Kazuhiko Uchida , Jun Uno , Yasushi Uchida , Osamu Shida
IPC分类号： A01N43/713 , A01N63/00 , A61K38/00 , A61P31/04 , C07K7/56 , C12P21/04 , C12R1/07 , A61K38/12
CPC分类号： A01N63/00 , A01N43/713 , C07K7/56 , Y10S435/832
摘要： The present invention is a method of producing iturin A, in which cells of Bacillus amyloliquefaciens are incubated and iturin A is collected from the culture. It also relates to an antifungal agent for profound mycosis, containing iturin A as the active ingredient. Heretofore, there have been known few medicines effective against profound mycosis, but iturin A may be an effective antifungal agent for profound mycosis.
摘要翻译：本发明是一种生产神经蛋白A的方法，其中培养解淀粉芽孢杆菌的细胞并从培养物中收集神经蛋白A. 它还涉及含有神经蛋白A作为活性成分的深度真菌病的抗真菌剂。迄今为止，已知有几种对深层真菌病有效的药物，但是，对于深层真菌病，神经蛋白A可能是有效的抗真菌剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式